Pre-Analytical Sampling and Storage Conditions of Amyloid-β Peptides in Venous and Capillary Blood-Reference-Cited by-同舟云学术

Pre-Analytical Sampling and Storage Conditions of Amyloid-β Peptides in Venous and Capillary Blood

Published:2020-11-10 Issue:2 Volume:78 Page:529-535
ISSN:1387-2877
Container-title:Journal of Alzheimer's Disease
language:
Short-container-title:JAD

Author:

Walter Marlena¹,Wiltfang Jens¹²³,Vogelgsang Jonathan¹⁴⁵

Affiliation:

1. University Medical Center Goettingen (UMG), Georg-August-University, Department of Psychiatry and Psychotherapy, Goettingen, Germany

2. German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany

3. iBiMED, Medical Science Department, University of Aveiro, Portugal

4. University Medical Center Goettingen (UMG), Georg-August-University, Clinician Scientist College, Goettingen, Germany

5. McLean Hospital, Harvard Medical School, Translational Neuroscience Laboratory, Belmont, MA, USA

Abstract

Previous studies on blood-based biomarkers for Alzheimer’s disease suggest a less invasive blood test might be a valuable screening tool for Alzheimer-specific pathology. Pre-analytical sample storage conditions seem to play an important role on amyloid-β (Aβ) stability, impacting reliability and reproducibility. This study shows that Aβ40, Aβ42, and Aβ42/40 levels significantly and early decrease during storage at room temperature in whole blood or plasma. Storing blood samples at 4°C leads to stable Aβ peptide concentrations up to 72 h. In addition, Aβ peptides can be measured in capillary blood with a stable Aβ42/40 ratio up to 72 h at 4°C.

Publisher

IOS Press

Subject

Psychiatry and Mental health,Geriatrics and Gerontology,Clinical Psychology,General Medicine,General Neuroscience

Reference18 articles.

1. 2019 Alzheimer’s disease facts and figures;Alzheimer’s Association;Alzheimers Dement,2019

2. Isolation and chemical characterization of Alzheimer’s disease paired helical filament cytoskeletons: Differentiation from amyloid plaque core protein;Roher;J Cell Biol,1988

3. CSF markers for incipient Alzheimer’s disease;Blennow;Lancet Neurol,2003

4. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease;Sevigny;Nature,2016

5. Questions EMERGE as Biogen claims aducanumab turnaround;Howard;Nat Rev Neurol,2020

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting;Molecular Neurodegeneration;2024-05-15

2. New plasma LC-MS/MS assays for the quantitation of beta-amyloid peptides and identification of apolipoprotein E proteoforms for Alzheimer’s disease risk assessment;Journal of Investigative Medicine;2024-04-30

3. Clinical utility of plasma Aβ42/40 ratio by LC-MS/MS in Alzheimer’s disease assessment;Frontiers in Neurology;2024-03-25

4. Clinical utility of plasma Aβ42/40 ratio by LC-MS/MS in Alzheimer’s disease assessment;2023-12-14

5. New plasma LC-MS/MS assays for the quantitation of beta-amyloid peptides and identification of apolipoprotein E proteoforms for Alzheimer’s disease risk assessment;2023-11-22